MENU

Board of Directors

Alnylam’s Board of Directors is composed of accomplished leaders from the healthcare industry who bring their experience in science, drug development, commercialization and strategy to our efforts in developing RNAi therapeutics.

Michael W. Bonney (Chairman)

Former Chief Executive Officer and Director of Cubist Pharmaceuticals and former Partner of Third Rock Ventures; Director of Celgene Corporation, Global Blood Therapeutics, Inc., and Revolution Medicines, Inc.; and Trustee of Gulf of Maine Research Institute and TEKLA fund complex, focused on healthcare investing.


Dennis A. Ausiello, M.D.

Director of the Center for Assessment Technology and Continuous Health (CATCH), Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Massachusetts General Hospital; director of Pfizer, Inc. and Seres Therapeutics, Inc.


John K. Clarke

Managing General Partner, Cardinal Partners; founder of Alnylam, Alkermes, Inc. and Cubist Pharmaceuticals, Inc. and Chairman of the Board of Directors of aTyr Pharma, Inc.


Marsha H. Fanucci

Former Chief Financial Officer of Millennium Pharmaceuticals and serves on the Board of Directors at Ironwood Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc.


John M. Maraganore, Ph.D.

Chief Executive Officer of Alnylam and serves on the Board of Directors at bluebird bio, Inc. and Agios Pharmaceuticals.


Steven M. Paul, M.D.

Chief Executive Officer, President and board member of Voyager Therapeutics, Inc.; Venture Partner at Third Rock Ventures; co-founder and board member of SAGE Therapeutics; trustee for the Foundation for the National Institute of Mental Health (NIH); former President of the Lilly Research Laboratories of Eli Lilly and Company and former Scientific Director of the National Institute of Mental Health.


David E.I. Pyott

Former Chairman and Chief Executive Officer of Allergan; Lead Director of Avery Dennison Corporation; member of the Supervisory Board of Royal Philips in the Netherlands and director of BioMarin Pharmaceuticals, Inc.


Paul R. Schimmel, Ph.D.

Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute; founder of Alnylam; member of the National Academy of Sciences, American Academy of Arts and Sciences and the Institute of Medicine; co-founder of Cubist, Alkermes and Repligen; and co-founder and director of aTyr Pharma, Inc.


Amy W. Schulman

Co-founder and Chief Executive Officer of Lyndra, Inc.; Executive Chair of SQZ Biotech; Venture Partner at Polaris Partners; Former Executive Vice President and General Counsel of Pfizer Inc.; served as the Business Unit Lead for Pfizer’s Consumer Healthcare and Nutrition businesses; senior lecturer at Harvard Business School and director of Ironwood Pharmaceuticals, Inc. and Blue Buffalo Pet Products, Inc.


Phillip A. Sharp, Ph.D.

Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; founding director of McGovern Institute for Brain Research, MIT; Nobel Laureate; founder of Alnylam; co-founder and former director of Biogen, Inc.; member of the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.


Kevin P. Starr, Partner

Third Rock Ventures partner; Chairman and Interim Chief Executive Officer of Decibel Therapeutics, Inc.; former Chief Operating Officer and Chief Financial Officer of Millennium Pharmaceuticals, Inc.; director of Ember Therapeutics and SAGE Therapeutics, Inc.